FDA
-
-
-
-
-
-
-
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
-
-
-
-
-
-
-
Galmed Pharma (GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
-
-
-
-
-
-
-
Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects
-
-
-
-
-
-
-
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
-
-
-
-
-
-
-
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
-
-
-
-
-
-
-
Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares
-
-
-
-
-
-
-
Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
-
322,209 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

